Abstract:Background: Cancer vaccines represent a promising strategy for antitumor immunotherapy. Despite considerable research efforts and progress, the effectiveness of cancer vaccines remains a challenge. This is primarily due to relatively low immune responses against tumors, stemming from issues of poor immunogenicity and the immunosuppressive microenvironment commonly found in many solid tumors. Use of an optimal adjuvant can augment immune responses against tumor antigens and guide them towards a specific adaptive immune enhancement. Dendritic cells (DCs) play a primary role in initiating immunes response to vaccines, often through activation of toll-like receptors (TLRs). Identifying novel immunomodulatory proteins that regulate DCs or TLR activation can identify novel adjuvant candidates with applications for cancer immunotherapy. Methods: We constructed a Membrane Proteome Array (MPA) encompassing ~6,000 structurally intact human membrane proteins in their native conformation (94% of the entire membrane proteome) and used it to screen for cellular proteins that can modulate response to vaccination through DCs and TLRs. To identify proteins that interact with TLRs, the library was expressed in live TLR reporter cells, and these cells were tested for response to known activators. In addition, cells expressing the MPA were presented to DCs to identify membrane proteins that modulate DC activity. TLR-expressing cell activation was measuring using an NF-kB-activated luciferase reporter, while DC assays used upregulation of cell surface markers (CD80, CD83, and MHCII) to measure the activation of immature monocyte-derived dendritic cells. Results: Screening of TLR2, TLR3, and TLR5 reporter cell lines identified both known and novel regulators of TLR activation. Activators common to several TLRs were identified as well as activators unique to individual TLRs. Screening of primary human DCs likewise identified known regulators of activation (for example CD40L) and several novel targets. Putative novel regulators of DC activation are being further investigated to determine their biological significance. Conclusion: Discovering novel immunomodulatory targets and proteins that regulate DCs and TLR activation can identify novel adjuvant candidates with targeted immune outcomes, such as immune stimulating and anti-cancer responses. This study identified novel regulators of immune activation which are being further investigated as adjuvant candidates for cancer vaccines. Citation Format: Joseph Rucker, Nnenna Nwogu, Nicholas M. Molino, Ami Snyder, Jonathan T. Sullivan, Benjamin J. Doranz. Identifying new cellular adjuvants for cancer vaccines and immunotherapies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6743.

Adjuvant for vaccine immunotherapy of cancer – focusing on Toll‐like receptor 2 and 3 agonists for safely enhancing antitumor immunity

TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases

Tlr Agonists Activate Hpv11 E7-Pulsed Dcs to Promote A Specific T Cell Response in A Murine Model

Abstract 6743: Identifying new cellular adjuvants for cancer vaccines and immunotherapies

Adjuvant engineering for cancer immunotherapy: Development of a synthetic TLR2 ligand with increased cell adhesion

Toward Establishing an Ideal Adjuvant for Non-Inflammatory Immune Enhancement

Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles

Pathogen-like Nanoassemblies of Covalently Linked TLR Agonists Enhance CD8 and NK Cell-Mediated Antitumor Immunity

Dual TLR Agonist Nanodiscs As a Strong Adjuvant System for Vaccines and Immunotherapy

Recent Advances in the Development of Toll-like Receptor Agonist-Based Vaccine Adjuvants for Infectious Diseases

The TLR7 Agonists Imiquimod and Gardiquimod Improve DC-based Immunotherapy for Melanoma in Mice.

Adjuvant-Enhanced Antibody Responses In The Absence Of Toll-Like Receptor Signaling

A Toll-like receptor 3 (TLR3) agonist ARNAX for therapeutic immunotherapy

Emerging Adjuvants For Cancer Immunotherapy

The Novel Toll-Like Receptor 2 Agonist Sup3 Enhances Antigen Presentation and T Cell Activation by Dendritic Cells

Improvement of DC-based vaccines using adjuvant TLR4-binding 60S acidic ribosomal protein P2 and immune checkpoint inhibitors

Codelivery of Nod2 and Tlr9 Ligands Via Nanoengineered Protein Antigen Particles for Improving and Tuning Immune Responses

Toll-like Receptor-Targeted Nanoparticles: A Powerful Combination for Tumor Immunotherapy

Identification of a Novel Toll-Like Receptor-Independent Immunoadjuvant Pathway That Depends Upon Programmed Cell Death.

Adenovirus-mediated gene transfer of pathogen-associated molecular patterns for cancer immunotherapy

Maximizing TLR9 Activation in Cancer Immunotherapy with Dual-Adjuvanted Spherical Nucleic Acids